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Antibody drug conjugates (ADCs) are emerging as powerful treatment strategies with
outstanding target specificity and high therapeutic activity in cancer patients.
While >30 ADCs are currently being investigated in clinical trials, brentuximabvedotin
and T-DM1 represent clinically approved ADCs in cancer patients. We hypothesized
that their sustained clinical responses could be related to the stimulation of an
antitumor immune response. Indeed, the two microtubule-destabilizing agents
Dolastatin 10 and Ansamitocin P3, from which the cytotoxic components of
brentuximabvedotin and T-DM1 are derived, may serve as prototypes for a class of
agents that induce tumor cell death and convert tumor resident, tolerogenic dendritic
cells (DCs) into efficient antigen presenting cells (APCs). The two drugs induced
phenotypic and functional maturation of murine splenic as well as human
monocyte-derived DCs. In contrast, microtubule-stabilizing agents such as taxanes did
not display this feature. In tumor models, both Dolastatin 10 and Ansamitocin P3
efficiently promoted antigen uptake and migration of tumor-resident DCs to
tumor-draining lymph nodes, thereby potentiating tumor-specific T cell responses.
Underlining the requirement of an intact host immune system for the full therapeutic
benefit of these two compounds, their antitumor effect was far less pronounced in mice
lacking adaptive immunity or dendritic cells. Combinations with immune checkpoint
inhibition (anti-CTLA-4/-PD-1) did further augment antitumor immunity and tumor
rejection, which was reflected by reduced Treg numbers and elevated effector function
of tumor resident T cells. Ultimately, we were able to demonstrate peripheral immune
cell activation and brisk T cell infiltration into tumors in patients previously treated
with BrentuximabVedotin. Experiments are currently ongoing to investigate the
immunological mode of action of T-DM1 using orthotopic breast cancer models and
patients undergoing treatment. Our data reveal a novel mode of action for
microtubule-depolymerizing agents and provide a strong rationale for clinical
treatment regimens combining these with immune-based therapies.
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